Prop 38 pitches $8.4B immunology research fund amid NIH funding fight

California's Yes on Proposition 38 campaign is framing the ballot measure as a safeguard for medical research as the White House moves to tighten control over NIH grants. The measure would direct $8.4 billion toward immunology research, with the goal of speeding new treatments for cancer, Alzheimer’s, heart disease and other diseases.

Why it matters: - Prop 38 would create a new funding stream for immunology research at a moment when the White House is seeking more control over NIH grant decisions. - Supporters say the measure could help speed treatments and cures for diseases that affect millions of patients, including cancer, Alzheimer’s, heart disease and autoimmune disorders. - The campaign is positioning the ballot measure as a state-level backstop if federal research support becomes more politically constrained.

What happened: - The Yes on Proposition 38 campaign, also called the Immunology Medical Research & Cures Initiative, is urging California voters to approve the measure. - The campaign released its pitch after The New York Times reported that the White House is drafting a new executive order that could expand President Trump’s control over billions of dollars in NIH scientific grants. - The campaign says Prop 38 would provide $8.4 billion for immunology research and related medical innovation.

The details: - Half of the money would go to competitive grants at California universities and nonprofit research institutions. - The other half would fund a nonprofit immunology institute affiliated with the University of California. - The institute is intended to bring together scientists, technology, laboratories, patients and clinical trials. - The campaign says immunotherapies already help treat melanoma, lung cancer, leukemia and lymphoma. - The measure is also aimed at research on Alzheimer’s, Parkinson’s, ALS, heart disease, diabetes, muscular dystrophy, rheumatoid arthritis, lupus and multiple sclerosis. - Prop 38 includes a funding mechanism that requires 10% of proceeds from the licensing of immunotherapies to be returned to California to offset costs, including interest. - The measure says Californians who receive a cure or immunotherapy developed under the program would get a 20% discount below the national average. - Accountability provisions include a 2% cap on state administrative expenses, public spending disclosure, independent financial audits and a ban on grant funding for for-profit corporations. - The campaign directs supporters to YESon38.com for more information, including coalition details and supporter statements.

Between the lines: - The campaign is tying a state tax-and-spend proposal to a broader national fight over who controls federal science funding. - By emphasizing diseases with high public concern, Prop 38 is selling research spending as both a public health issue and a political hedge against federal uncertainty. - The structure of the proposal suggests an effort to appeal to voters who want both scientific investment and stricter oversight.

What's next: - The campaign will press voters to back Prop 38 ahead of the election. - If approved, the measure would launch a statewide research network and immunology institute built around grant funding and commercialization returns. - Future debate is likely to focus on whether the projected licensing revenue can reliably offset the program’s costs and whether the proposed governance limits are sufficient.

The bottom line: - Prop 38 is being sold as a California answer to federal research uncertainty: a big, tightly controlled bet on immunology science and the promise of future cures.